These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 32979351)

  • 1. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
    Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
    Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
    Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
    J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.
    Gray LR; On H; Roberts E; Lu HK; Moso MA; Raison JA; Papaioannou C; Cheng WJ; Ellett AM; Jacobson JC; Purcell DF; Wesselingh SL; Gorry PR; Lewin SR; Churchill MJ
    J Neurovirol; 2016 Aug; 22(4):455-63. PubMed ID: 26727904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
    Bricker KM; Chahroudi A; Mavigner M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV "shock and kill" therapy: In need of revision.
    Abner E; Jordan A
    Antiviral Res; 2019 Jun; 166():19-34. PubMed ID: 30914265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.